Foresee Pharmaceuticals CoROCO:6576 58 Current Ratio is 3.44 as of Dec. 2025, which is 35% below its 10-year median of 5.26. GuruFocus rates ROCO:6576 with a GF Score™ of 58/100 and a GF Value™ of NT$96.69 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 998 Drug Manufacturers companies, Foresee Pharmaceuticals Co ranks better than 72.04% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Foresee Pharmaceuticals Co's current ratio for the quarter that ended in Dec. 2025 was 3.44.
Foresee Pharmaceuticals Co has a current ratio of 3.44. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Foresee Pharmaceuticals Co's Current Ratio or its related term are showing as below:
ROCO:6576'
s Current Ratio Range Over the Past 10 Years
Min: 2.55 Med: 5.26 Max: 17.51
Current: 3.44
During the past 12 years, Foresee Pharmaceuticals Co's highest Current Ratio was 17.51. The lowest was 2.55. And the median was 5.26.
ROCO:6576's Current Ratio is ranked better than 72.04% of 998
companies
in the Drug Manufacturers industry
Industry Median: 2
vs ROCO:6576: 3.44
Foresee Pharmaceuticals Co (ROCO:6576) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Foresee Pharmaceuticals Co Current Ratio Related Terms
Foresee Pharmaceuticals Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Foresee Pharmaceuticals Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foresee Pharmaceuticals Co Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Foresee Pharmaceuticals Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Foresee Pharmaceuticals Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Foresee Pharmaceuticals Co (ROCO:6576) has a Current Ratio of 3.44 as of Dec. 2025. This is 35% below median its historical median of 5.26. Over the past decade, Foresee Pharmaceuticals Co's Current Ratio has ranged from 2.55 to 17.51. According to the industry distribution chart, Foresee Pharmaceuticals Co ranks #279 out of 998 companies in the Drug Manufacturers industry, placing it in the top 28%.
Is Foresee Pharmaceuticals Co's Current Ratio too high?
Foresee Pharmaceuticals Co's current Current Ratio of 3.44 is 35% below median its 10-year median of 5.26. Over the past 10 years, this metric has ranged from a low of 2.55 to a high of 17.51. The Drug Manufacturers industry median Current Ratio is 2.00. Foresee Pharmaceuticals Co's value of 3.44 is 72% above this industry median. Based on the distribution chart, Foresee Pharmaceuticals Co ranks #279 out of 998 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Foresee Pharmaceuticals Co has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Foresee Pharmaceuticals Co's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Foresee Pharmaceuticals Co ranks #279 out of 998 companies for Current Ratio. This puts Foresee Pharmaceuticals Co in the upper half of its industry. The industry median Current Ratio is 2.00. Foresee Pharmaceuticals Co's value of 3.44 is 72% above this benchmark. Historically, Foresee Pharmaceuticals Co's own Current Ratio has ranged from 2.55 to 17.51 over the past decade. While the company's 10-year median is 5.26 vs. the industry median of 2.00, Foresee Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Foresee Pharmaceuticals Co's current Current Ratio of 3.44 is 72% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Foresee Pharmaceuticals Co's current Current Ratio is 3.44, which is 35% below median its own 10-year median of 5.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foresee Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co (ROCO:6576) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$96.69, compared to a current price of NT$83.10 — trading 14.1% below its estimated fair value. The current Current Ratio is 3.44, which is 35% below median its 10-year median of 5.26 and 72% above the Drug Manufacturers industry median of 2.00. Foresee Pharmaceuticals Co's overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Foresee Pharmaceuticals Co (ROCO:6576), the current Current Ratio is 3.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Foresee Pharmaceuticals Co (ROCO:6576) Overvalued in 2026?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$83.10 is trading 14.1% below its estimated GF Value™ of NT$96.69.
GuruFocus considers Foresee Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for ROCO:6576:
Current Ratio: 3.44 (35% below median its 10-year median of 5.26)
GF Value™: NT$96.69 vs. price of NT$83.10 (14.1% below fair value)
Industry Position: 72% above the Drug Manufacturers median (#279 of 998)
No single metric tells the full story. See the ROCO:6576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Foresee Pharmaceuticals Co Ltd main activity is applying stabilized injectable formulation (SIF) platform technology to produce products for anticancer and treatment of chronic diseases. Its pipeline includes CAMCEVI (Leuprolide, FP-001), FP-014 (Triptorelin), Aderamastat (FP-025, MMP-12 Inhibitor), Linvemastat (FP-020, MMP-12 Inhibitor), and others. The Group operates business only in a single industry of new drug development, and all of its revenue is generated from Taiwan.
58GF Score
Get the complete analysis for ROCO:6576
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6576 has been successfully added to your 
